Antiplatelet drug use preceding the onset of intracerebral hemorrhage is associated with increased mortality.
Recent studies highlight the contribution of antiplatelet therapy to clinical severity and increased mortality of intracerebral hemorrhage (ICH) but results are discrepant. The aim of this report was to evaluate the association between antiplatelet drug use preceding the onset of ICH and the mortality, assessed at regular intervals, among patients with acute ICH. We analyzed data from a randomized study which enrolled consecutive patients with a documented acute ICH to evaluate the efficacy of intermittent pneumatic compression of the legs in venous thrombosis prevention. Clinical characteristics and treatment used before the onset of ICH were checked at the time of inclusion. Mortality was assessed at regular intervals until 3 months after ICH diagnosis. Among 138 patients included in this report, 30 were current users of antiplatelet therapy at the time of ICH; they were significantly older and less frequently heavy drinkers than non-users of antiplatelet drugs. Mortality rates were 20% at 8 days, 40% at 1 month, and 47% at 3 months among antiplatelet drug users compared with 6.5%, 13% and 19% among non-users. The corresponding estimated risks for mortality related to antiplatelet drug use were 3.6 (95% CI 1.1-12), 4.5 (95% CI 1.8-11), and 3.6 (95% CI 1.5-8.6). Adjusted for age, hypertension and alcohol over use, antiplatelet therapy remained significantly associated with an increased mortality rate of acute ICH. Current antiplatelet drug use preceding the onset of ICH is associated with increased short-term ICH mortality, independently of age.
Lacut
Karine
K
Department of Internal Medicine and Chest Diseases, G.E.T.B.O. (Groupe d'Etude de la Thrombose de Bretagne Occidentale), Brest Cedex, France. karine.lacut@chu-brest.fr
Le Gal
Gregoire
G
Seizeur
Romuald
R
Prat
Gwenael
G
Mottier
Dominique
D
Oger
Emmanuel
E
D000368:Aged; D002543:Cerebral Hemorrhage / Q000209:etiology / Q000401:mortality*; D005260:Female; D006801:Humans; D048228:Intermittent Pneumatic Compression Devices; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D020246:Venous Thrombosis / Q000517:prevention & control
D010975:Platelet Aggregation Inhibitors